Companies › Akebia Therapeutics
3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Genitourinary, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Praliciguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Focal Segmental Glomerulosclerosis | Jun 2027 |
| ADX-097 | – | Phase 2 | IgA Nephropathy | Feb 2028 |
| AKB-9090 | – | Phase 1 | Healthy Volunteers | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07429006 | AKB-9090 | Phase 1 | Healthy Volunteers | Other | Dec 2026 |
| NCT07268638 | Praliciguat | Phase 2 | Focal Segmental Glomerulosclerosis | Genitourinary | Jun 2027 |
| NCT06419205 | ADX-097 | Phase 2 | IgA Nephropathy | Genitourinary | Feb 2028 |
Cash of $159m on 2026-09-30; operating cash outflow about $21m a year; runway about 93 months at that burn, to Jun 2034; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Jade Biosciences Clinique Ovo Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Neurocrine Switzerland Shanghai Bao Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.